Product Description
Torasemide (torsemide) is a high-ceiling loop diuretic which acts on the thick ascending limb of the loop of Henle to promote rapid and marked excretion of water, sodium and chloride. Like furosemide (frusemide), its major site of action is from the luminal side of the cell. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1706990/)
Mechanisms of Action: NKCC Inhibitor,Chloride Ion Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Dominican Republic | Egypt | Estonia | European Medicines Agency | Germany | Greece | India | Ireland | Italy | Jordan | Korea | Latvia | Lithuania | Luxembourg | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Ferrer Internacional
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: India, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Heart Failure|Overactive Bladder|Urinary Incontinence
Phase 1: Body Weight Changes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SAR065-224 | P2 |
Recruiting |
Heart Failure |
2025-08-01 |
|
| SAR065-124 | P2 |
Recruiting |
Urinary Incontinence|Heart Failure|Overactive Bladder |
2025-02-01 |
24% |
| CLCD-075-17 | P1 |
Completed |
Body Weight Changes |
2022-06-30 |
21% |